News All necessary regulatory approvals have been obtained for the combination of Novozymes and Chr. Hansen Staff January 26, 2024 Please read the full announcement in PDF Attachment 2024_01_All_Regulatory_Approvals_Obtained Iframe sync Post navigation Previous: Additional ODM-208/MK-5684 Phase II data presented at ASCO-GU 2024Next: All necessary regulatory approvals have been obtained for the combination of Novozymes and Chr. Hansen More Stories Cancer Diagnostics DNA Medicare News Patient Care Pharmaceutical Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting Staff December 6, 2025 Cancer Clinical Trial News Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition Staff December 6, 2025 Cancer Clinical Trial News Pharmaceutical Io Therapeutics presents today at the American Society for Hematology Annual Meeting, preclinical studies demonstrating combination treatment with BCMA CAR-T cells plus the company’s RXR agonist compound IRX4204 has synergistic efficacy against human multiple myeloma Staff December 6, 2025
